145206-40-2 Usage
General Description
BOC-L-2-FURYLALANINE DCHA SALT is a chemical compound that consists of a BOC (tert-butyloxycarbonyl) protected form of L-2-furylalanine, combined with DCHA (4-dimethylaminopyridine-3-sulfonyl chloride) as a salt. BOC-L-2-FURYLALANINE DCHA SALT is commonly used as a building block in peptide synthesis, where the BOC group serves as a temporary protecting group that can be removed under mild conditions to reveal the free amine. The presence of the furan ring in the molecule imparts unique properties and reactivity, making it useful in the development of novel peptide-based therapeutics and research applications. Additionally, the DCHA salt form improves the solubility and stability of the compound, facilitating its handling and storage in laboratory settings.
Check Digit Verification of cas no
The CAS Registry Mumber 145206-40-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,5,2,0 and 6 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 145206-40:
(8*1)+(7*4)+(6*5)+(5*2)+(4*0)+(3*6)+(2*4)+(1*0)=102
102 % 10 = 2
So 145206-40-2 is a valid CAS Registry Number.
InChI:InChI=1/C12H17NO5.C12H23N/c1-12(2,3)18-11(16)13-9(10(14)15)7-8-5-4-6-17-8;1-3-7-11(8-4-1)13-12-9-5-2-6-10-12/h4-6,9H,7H2,1-3H3,(H,13,16)(H,14,15);11-13H,1-10H2/t9-;/m1./s1
145206-40-2Relevant articles and documents
Enantioselective synthesis of dihydrofuranylglycine, furanylglycine, furanylalanine and homo-furanylalanine derivatives
Chattopadhyay, Shital K.,Sarkar, Kaushik,Karmakar, Swastik
, p. 2083 - 2085 (2005)
Enantiomerically pure nor-furanomycin, furanylglycine, furanylalanine and homo-furanylalanine derivatives were prepared from appropriate amino acid derived dienes using ring-closing metathesis as the key step. Georg Thieme Verlag Stuttgart.
PYRROLIDINONE GLUCOKINASE ACTIVATORS
-
Page/Page column 38, (2009/10/30)
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.
